BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25178561)

  • 1. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.
    Steffens S; Janssen M; Roos FC; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Hasenfus A; Kuczyk MA; Junker K; Schrader AJ;
    Hum Pathol; 2014 Dec; 45(12):2411-6. PubMed ID: 25305793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
    Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
    Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of clinicopathological features and prognosis in 68 patients with chromophobe renal cell carcinoma].
    Huang JW; Zhang J; Dong BJ; Kong W; Niu SX; Chen YH; Xue W; Liu DM; Huang YR
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):510-3. PubMed ID: 22967469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
    Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
    Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma.
    Chen SH; Xu LY; Wu YP; Ke ZB; Huang P; Lin F; Li XD; Xue XY; Wei Y; Zheng QS; Xu N
    BMC Cancer; 2021 Jan; 21(1):79. PubMed ID: 33468079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
    Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
    Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
    Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
    World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
    May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
    Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
    Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
    Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
    Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
    Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.